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Objective: Obesity and obstructive sleep apnea (OSA) and systemic inflammation may interact
through biochemical pathways. Neopterin (NP) is a monocyte/macrophage activation marker
produced by macrophages in response to interferon-gamma secreted by activated T-lympho-
cytes. This study examines the association between NP, obesity and OSA.
Patients and methods: The study included 22 newly diagnosed OSA (þ) patients and 18 OSA ()
patients. Subjects with history of coronary artery disease, transplant patients, history of alco-
hol and drug abuse, history of HIV and any other significant medical illnesses such as active in-
fections, autoimmune disease, malignancy, liver disease, pulmonary disease (COPD,
asthma,.), neuromuscular disease, patients on immunomodulating therapy or HMG-CoA re-
ductase inhibitors were excluded.
Results: There were no significant differences in age, bodymass index (BMI), and smoking habits
of the OSA (þ) patients and OSA () patients. SerumNP levels did not show any significant differ-
ence between theOSA (þ) patients andOSA () patients, however, NP levels were positively cor-
relatedwith BMI (rZ 0.320, pZ 0.044). Therewas no significant correlation betweenNPandany
of the polysomnographic parameters. The result of stepwise regression analyses (r2Z 0.320,
p< 0.001) showed that high serum NP levels (pZ 0.004) and apneaehypopnea index (AHI) were
a risk factor for elevated Epworth sleepiness score, independent of BMI.
Conclusion: We suggest that serumNP levels correlate with BMI. Therewas a significant relation-
ship between serum NP levels and excessive daytime sleepiness in OSA patients.
ª 2008 Elsevier Ltd. All rights reserved.ersitesi Tıp Faku¨ltesi, Go¨g˘u¨s Hastalıkları ve Tu¨berku¨loz AD, 16059 Go¨ru¨kle, Bursa, Turkey. Tel.: þ90
ail.com (A. Ursavasx).
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1194 A. Ursavasx et al.Introduction Sleep studyObstructive sleep apnea (OSA) is characterized by repeti-
tive collapse of the upper airway during sleep, resulting in
obstruction of airflow and oxygen desaturation, which
cause arousal from sleep.1 OSA is a common disorder in
the adult population, strongly associated with obesity. Obe-
sity is a major public health problem. There is a causal re-
lationship between OSA and obesity. OSA is present in
approximately 40% of obese individuals, and approximately
70% of OSA patients are obese.2
Several studies have demonstrated that OSA may be
one of the most important risk factors for cardiovascular
disease (CVD).3,4 The exact mechanism of cardiovascular
disease development in patients with OSA is unknown.
Several possible mechanisms such as increased sympa-
thetic activation, increased oxidative stress, increased
platelet aggregation, metabolic dysregulation, inflamma-
tion, and systemic vascular endothelial dysfunction are
suggested.5 In addition, adipocytes can produce inflam-
matory cytokines. There is also a relationship between
obesity, cardiovascular risk and inflammation.6 Neopterin
(NP) is an aromatic pteridine and a by-product of the gua-
nosine triphosphate biopterine pathway. NP is produced
by macrophages that are stimulated by interferon-gamma
(IFN-gamma) secreted by activated T-lymphocytes.7,8
Some studies have shown that elevated serum NP level
may be used as a monocyte/macrophage activation
marker.9,10
In the present study, we hypothesized that OSA and/or
obesity may elevate NP. In order to test this hypothesis, we
compared serum NP levels between OSA patients and
nonapneic controls.Materials and methods
Subjects
A cross-sectional study was performed, including subjects
referred to the same sleep center for the evaluation of
suspected OSA. The study was planned according to the
ethics guidelines of the Helsinki Declaration and was
approved by the Institutional Research Ethics Board of
Uludag˘ University Medical Hospital, Bursa, Turkey. All
patients gave written informed consent regarding partic-
ipation in this study. The exclusion criteria were history
of coronary artery disease, transplant patients, history of
alcohol and drug abuse, history of HIV and any other
significant medical illnesses such as active infections,
autoimmune disease, malignancy, liver disease, pulmo-
nary disease (COPD, asthma,.), neuromuscular disease,
being on immunomodulating therapy and use of HMG-CoA
reductase inhibitors.
The questionnaire inquired about the presence of any
history of snoring, witnessed apnea and Epworth Sleepi-
ness Scale (ESS).11 Demographic information (age, gender,
and smoking habits) and anthropometric measurements
(height, weight, and BMI [body mass index: weight/height
{kg/m2}]) were obtained upon presentation to the sleep
center.Full polysomnography (PSG) monitoring was performed in
all patients using the Compumedics P-series Sleep System
(Compumedics Sleep, Melbourne, Australia). Polysomno-
graphic recordings were done with standard technique.
Sleep staging was performed according to the standard
criteria of Rechtschaffen and Kales.12 The sum of time
spent in apnea and hypopnea was divided by the total sleep
time to obtain the apneaehypopnea index (AHI). Subjects
with AHI 5 were considered to have OSA (þ). Subjects
with AHI< 5 were categorized as the OSA () patients.
Determination of NP levels
Venous blood was collected from all patients between
08:00 am and 09:00 am after the sleep study and
centrifuged at 4 C, 3000g for 10 min within 30 min of col-
lection. Serum samples were stored at 80 C until assess-
ment was carried out in batches at the end of recruitment.
Serum NP levels were determined by a commercially avail-
able enzyme immunoassay kit (Neopterin EIA kit, ARP,
Belmont, USA) according to the manufacturer’s instruc-
tions. Briefly, samples were placed into wells coated with
a polyclonal antibody having a high affinity for neopterin
and horseradish peroxidase conjugated antibody was added
for detection. After 2-h incubation at room temperature,
excess unbound conjugate was removed by washing. Then
color substrate (TMB) was placed into the wells. Absor-
bance was measured in a microplate reader at 450 nm.
The concentration of the NP was expressed as nanogram
per milliliter (ng/ml) as recommended in the kit. The
expected physiological ranges were 0.3e3.0 ng/ml.
Statistical analysis
Statistical analysis was performed using the SPSS package
for Windows, version 13.0. Comparisons of data between
OSA (þ) and OSA () patients were carried out by Student’s
t, Chi-Square and ManneWhitney U tests. Concordance of
normal distribution of all variables was calculated by Sha-
piroeWilk test before comparison between OSA (þ) and
OSA () patients. If the data were not normally distributed,
we used non-parametric tests for dependent variables. The
relationship between serum NP level and BMI was calcu-
lated using Pearson’s correlation analysis. We performed
stepwise regression analysis to identify significant relation-
ships between BMI, sleep disorder parameters and NP. p
value less than 0.05 was considered statistically significant.Results
Baseline characteristics
Sixty-five subjects with suspected OSA were screened for
the study. Twenty-five subjects were excluded. The study
included 22 consecutive newly diagnosed OSA (þ) patients
and 18 OSA () patients. Baseline clinical and polysomno-
graphic characteristics of the OSA (þ) and OSA () patients
are shown in Table 1. There was no significant difference in
Table 1 Baseline clinical and polysomnographic charac-
teristics of the study groups
OSA (þ) OSA () p value
Age 47.0 2.9 48.5 2.1 NS
Body mass index (kg/m2) 30.1 1.1 28.3 1.9 NS
Smoking habits (pack-years) 23.1 6.9 19.2 2.7 NS
Epworth sleepiness scale 8.4 1.1 4.6 0.8 <0.05
Total sleep time (TST) (h) 6.3 0.7 6.5 0.9 NS
Sleep efficiency (%) 81.3 2.2 81.1 1.9 NS
Stages 3 and 4 (% TST) 8.1 1.8 16.8 1.8 <0.05
Rapid eye movement
(% TST)
11.1 1.6 20.3 1.7 <0.05
AHI (per h) 47.0 4.6 2.1 0.3 e
Arousal (per h) 26.8 3.5 12.4 1.9 <0.05
Baseline oxygen
saturation (%)
93.7 2.5 94.3 1.1 NS
NS: statistically insignificant.
Sleep apnea and neopterin 1195age, gender, BMI, smoking habit, and snoring between the
two groups. In the OSA (þ) group, ESS scores were signifi-
cantly higher than those of the OSA () patients
(p< 0.05). There was no significant difference in the total
sleeping time, sleep efficiency, and baseline oxygen satura-
tion between the two groups. Significant differences were
noted in the sleep stages 3 and 4, number of arousals
(per hour), AHI, duration of apneaehypopnea, oxygen desa-
turation index, average oxygen saturation during sleep, av-
erage oxygen desaturation, and length of time spent with
an oxygen saturation <90% when the OSA (þ) group was
compared to OSA () patients (p< 0.001).
Serum NP levels
No significant difference was noted in the serum levels of
NP in OSA (þ) group (6.4 0.2 ng/ml) when compared to
OSA () patients (6.0 0.3 ng/ml). Serum NP levels were
positively correlated with BMI (rZ 0.320, pZ 0.044)45,0040,0035,0030,0025,0020,00
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Figure 1 Correlation coefficient between serum NP levels
and body mass index (BMI).(Fig. 1). There was no significant correlation between NP
and any polysomnographic parameters such as apneaehy-
popnea index (AHI), number of total apnea during the
night, number of respiratory events during the night, time
spent in apnea and hypopnea, respiratory arousal index, av-
erage oxygen desaturation and oxygen desaturation index.
The result of stepwise regression analyses [ESSZ NP
(0.411)þ AHI (0.367)þ BMI (0.141), r2Z 0.320, p< 0.001]
showed that NP (pZ 0.004) (Fig. 2) and AHI (pZ 0.009)
were risk factors for elevated ESS, independent of BMI.
Discussion
To our knowledge this is the first study to assess the
relationship between serum NP levels, obesity and OSA.
The results of the present study indicate that there is
a significant relationship between excessive daytime sleep-
iness, obesity and elevated serum NP levels.
NP is a sensitive marker of cellular immunity. Activated
lymphocytes produce IFN-gamma, which in turn activates
macrophages. Macrophages activated by IFN-gamma syn-
thesize NP. NP modulates the intracellular redox state and
it activates translocation of the nuclear factor kB subunits
to the nucleus. NP is upregulated by proinflammatory
genes.13,14 NP may be of clinical use as an early inflamma-
tion marker. Elevated NP concentrations are observed in
diseases with intensified monocyte/macrophage activity.
The NP concentrations also reflect the level of oxidative
stress caused by activation of the immune system.15
Inflammation plays an important role in atherogenesis and
plaque vulnerability. Monocytes/macrophages are culprit
cells in atherosclerotic plaque formation. Studies have re-
ported an association between NP and atherosclerosis.16e19
Activated lymphocytes in atherosclerotic plaques produce
a variety of cytokines such as IFN-gamma, amolecule activat-
ing macrophages. The levels of NP are elevated in patients
with acute as well as chronic coronary artery disease
(CAD).17 In addition, serum NP levels in patients with acute
myocardial infarction (AMI) were significantly higher than
chronic CAD and control subjects. NP is a marker of CAD9,008,007,006,005,004,003,002,00
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Figure 2 Regression line between Epworth sleepiness scale
and serum NP levels.
1196 A. Ursavasx et al.activity and it is a prognostic factor for acute coronary
syndrome (ACS).18
Morphological thickness of the arterial wall is an impor-
tant feature of atherosclerosis. Carotid arterial changes
can reflect the progression of systemic atherosclerosis in
asymptomatic general population. Erten et al.20 reported
a significant positive correlation between serum NP levels
and carotid intima media thickness (IMT) in hemodialysis
patients. They suggested that NP could be associated with
the severity of carotid atherosclerosis. Previous studies
showed that the carotid IMT is increased in patients with
obesity and/or severe OSA.21,22
Increasing evidence indicates the important role of
inflammation in the etiology of major public health
problems. Several studies have proposed that obesity
might be an inflammatory disorder. Obesity is closely
associated with a number of established cardiovascular
risk factors, including diabetes mellitus, insulin resis-
tance, dyslipidemia, CAD, and hypertension.23 Adipocytes
can produce inflammatory cytokines. Adipose tissue is
known to express and secrete a variety of products
known as ‘adipokines’, including leptin, adiponectin, re-
sistin and visfatin, as well as cytokines and chemokines
such as tumor necrosis factor-alpha, interleukin-6 and
monocyte chemoattractant protein-1.24 Recent data dem-
onstrate that obese adipose tissue is infiltrated by macro-
phages, which may be a major source of locally-produced
proinflammatory cytokines. Interestingly, weight loss is
associated with a reduction in the macrophage infiltration
of adipose tissue and an improvement of the inflamma-
tory profile of gene expression. Several factors derived
not only from adipocytes but also from infiltrated macro-
phages probably contribute to the pathogenesis of insulin
resistance.25 Ledochowski et al.26 reported that NP con-
centrations were significantly higher in patients with
elevated BMI and elevated glucose concentrations. They
also indicated that there were significant correlations
between glucose concentrations and BMI, as well as
between serum NP concentrations and BMI. Bozdemir
et al.27 investigated serum C-reactive protein (CRP) and
NP levels in healthy adults. They demonstrated that se-
rum NP levels were higher in group A (BMI 25 kg/m2)
than in group B (BMI< 25 kg/m2), but the differences
were not significant. Serum CRP and NP levels were sig-
nificantly higher in group C (waistehip ratio, WHR 0.9)
compared to those in group D (WHR< 0.9). In the present
study we showed that consistent with previous studies in
obese patients serum NP levels were positively correlated
with BMI.
Obesity can be associated with excessive daytime
sleepiness (EDS) even in the absence of OSA. EDS is
considered to be the major sign of OSA, however, the
relationship between EDS and AHI has been shown to be
weak.28 Bixler et al29 suggest that patients with a complaint
of EDS should be thoroughly assessed for depression, obe-
sity/diabetes and metabolic syndrome independent of
whether or not sleep disordered breathing is present. Re-
cent studies suggested that EDS may be more strongly asso-
ciated with obesity and inflammatory markers than to
AHI.30e32 In the present study, the result of stepwise regres-
sion analyses showed that ESS was a risk factor for high se-
rum NP levels, independent of AHI and BMI.In conclusion, we suggest that serum NP levels correlate
with BMI. There was a significant relationship between
serum NP levels and EDS in OSA patients.
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